GENMAB Inactive Instrument
Genmab Share Price Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
| Sales 2024 * | 19.66B 2.82B 235B | Sales 2025 * | 23.51B 3.37B 281B | Capitalization | 127B 18.18B 1,516B |
|---|---|---|---|---|---|
| Net income 2024 * | 5.11B 732M 61.05B | Net income 2025 * | 6.76B 969M 80.79B | EV / Sales 2024 * | 5.1 x |
| Net cash position 2024 * | 26.57B 3.81B 318B | Net cash position 2025 * | 33.5B 4.8B 401B | EV / Sales 2025 * | 3.97 x |
| P/E ratio 2024 * |
25
x | P/E ratio 2025 * |
19.2
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 01/99/01 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 01/07/01 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 23/20/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 01/17/01 |
| Director/Board Member | 73 | 01/03/01 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 63 | 01/16/01 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
02/05/2024
- Q1 2024 Earnings Release
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B | |
| -24.71% | 8.24B |
